Chapter 21 : Host Genetic Variation, Innate Immunity, and Susceptibility to Urinary Tract Infection

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in

Host Genetic Variation, Innate Immunity, and Susceptibility to Urinary Tract Infection, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555817213/9781555817084_Chap21-1.gif /docserver/preview/fulltext/10.1128/9781555817213/9781555817084_Chap21-2.gif


Microbial determinants of acute-disease severity and tissue damage have been extensively studied, but less is known about genetic variation influencing host susceptibility. This chapter discusses two candidate genes with strong effects on the innate immune response and the antibacterial defense in the urinary tract and with major but opposite effects on urinary tract infection (UTI) susceptibility. The chapter explains that defects in TLR4 expression are protective and associated with asymptomatic bacteriuria (ABU) while defects in CXCR1 expression promote acute pyelonephritis (APN) and renal scarring. C3H/HeJ mice, then known as lipopolysaccharide (LPS)-nonresponder mice, had an increased susceptibility to UTI, as shown by delayed bacterial clearance. It also had an impaired innate immune response, suggesting that defects in innate immunity are of great importance for the antibacterial defense of the urinary tract. Studies of the murine model showed that the antibacterial defense of the urinary tract mucosa relies on innate immunity and that TLR4 plays a central role in the early host defense against infection. The results suggest that genetic variation of the TLR4 promoter is an essential, largely overlooked mechanism to influence TLR4 expression and UTI susceptibility. It was found that the protein expression was reduced and additionally the level of CXCR1 transcript and protein expression was lower in this new subset of pediatric patients. There is a great clinical need to identify genetic variants that improve resistance or increase susceptibility to infectious pathogens.

Citation: Ragnarsdóttir B, Svanborg C. 2012. Host Genetic Variation, Innate Immunity, and Susceptibility to Urinary Tract Infection, p 358-378. In Hacker J, Dobrindt U, Kurth R (ed), Genome Plasticity and Infectious Diseases. ASM Press, Washington, DC. doi: 10.1128/9781555817213.ch21
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


Image of FIGURE 1

TLR4 is crucial for recognition of gram-negative bacteria and is best known as the LPS receptor. CD14 is a coreceptor for TLR4 and is essential for LPS recognition. Epithelial cells are, unlike macrophages and polymorphonuclear neutrophils, CD14 negative and as a result do not respond to LPS or commensal-like bacteria. However, epithelial cells respond in a pathogen-specific way and are activated by both P-and type 1-fimbriated but in different ways. P fimbriae bind to the Galα1-4Galb receptor epitope in the globoseries of glycosphingolipids (GSLs), resulting in ceramide release and activation of epithelial cells through a TLR4 and the TRIF/TRAM-dependent pathway. Type 1 fimbriae bind α-mannosylated glycoproteins (MGPs) and activate epithelial cells through TLR4 but through MyD88-dependent mechanisms. doi:10.1128/9781555817213.ch21f01

Citation: Ragnarsdóttir B, Svanborg C. 2012. Host Genetic Variation, Innate Immunity, and Susceptibility to Urinary Tract Infection, p 358-378. In Hacker J, Dobrindt U, Kurth R (ed), Genome Plasticity and Infectious Diseases. ASM Press, Washington, DC. doi: 10.1128/9781555817213.ch21
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 2

Three-generation pedigrees reveal a genetic predisposition to UTI. An accumulation of pyelonephritis was found in the relatives of the APN-prone patients (shown in red), while most of the UTI incidents in the control families were single episodes of cystitis (shown in gray), often associated with pregnancy. The arrows indicate the index APN-prone children. Partially reprinted from the ( ) with permission of the publisher. doi:10.1128/9781555817213.ch21f02

Citation: Ragnarsdóttir B, Svanborg C. 2012. Host Genetic Variation, Innate Immunity, and Susceptibility to Urinary Tract Infection, p 358-378. In Hacker J, Dobrindt U, Kurth R (ed), Genome Plasticity and Infectious Diseases. ASM Press, Washington, DC. doi: 10.1128/9781555817213.ch21
Permissions and Reprints Request Permissions
Download as Powerpoint


1. Agace, W.,, S. Hedges,, U. Andersson,, J. Andersson,, M. Ceska,, and C. Svanborg. 1993a. Selective cytokine production by epithelial cells following exposure to Escherichia coli. Infect. Immun. 61: 602 609.
2. Agace, W.,, S. Hedges,, M. Ceska,, and C. Svanborg. 1993b. IL-8 and the neutrophil response to mucosal Gram negative infection. J. Clin. Investig. 92: 780 785.
3. Ahuja, S. K.,, and P. M. Murphy 1996. The CXC chemokines growth-regulated oncogene (GRO) alpha, GRObeta, GROgamma, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor. J. Biol. Chem. 271: 20545 20550.
4. Allen, A.,, S. Obaro,, K. Bojang,, A. A. Awomoyi,, B. M. Greenwood,, H. Whittle,, G. Sirugo,, and M. J. Newport. 2003. Variation in Toll-like receptor 4 and susceptibility to group A meningococcal meningitis in Gambian children. Pediatr. Infect. Dis. J. 22: 1018 1019.
5. Anderson, K. V.,, G. Jurgens,, and C. Nusslein-Volhard. 1985. Establishment of dorsal-ventral polarity in the Drosophila embryo: genetic studies on the role of the Toll gene product. Cell 42: 779 789.
6. Arbour, N. C.,, E. Lorenz,, B. C. Schutte,, J. Zabner,, J. N. Kline,, M. Jones,, K. Frees,, J. L. Watt,, and D. A. Schwartz. 2000. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat. Genet. 25: 187 191.
7. Backhed, F.,, L. Meijer,, S. Normark,, and A. Richter-Dahlfors. 2002. TLR4-dependent recognition of lipopolysaccharide by epithelial cells requires sCD14. Cell. Microbiol. 4: 493 501.
8. Baggiolini, M. 1998. Chemokines and leukocyte traffic. Nature 392: 565 568.
9. Bergsten, G.,, M. Samuelsson,, B. Wullt,, I. Leijonhufvud,, H. Fischer,, and C. Svanborg. 2004. PapG-dependent adherence breaks mucosal inertia and triggers the innate host response. J. Infect. Dis. 189: 1734 1742.
10. Bergsten, G.,, B. Wullt,, and C. Svanborg. 2005. Escherichia coli, fimbriae, bacterial persistence and host response induction in the human urinary tract. Int. J. Med. Microbiol. 295: 487 502.
11. Bianchi, M. E. 2007. DAMPs, PAMPs and alarmins: all we need to know about danger. J. Leukoc. Biol. 81: 1 5.
12. Bihl, F.,, L. Salez,, M. Beaubier,, D. Torres,, L. Lariviere,, L. Laroche,, A. Benedetto,, D. Martel,, J. M. Lapointe,, B. Ryffel,, and D. Malo. 2003. Overexpression of Toll-like receptor 4 amplifies the host response to lipopolysaccharide and provides a survival advantage in transgenic mice. J. Immunol. 170: 6141 6150.
13. Bowie, A.,, E. Kiss-Toth,, J. A. Symons,, G. L. Smith,, S. K. Dower,, and L. A. O’Neill. 2000. A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling. Proc. Natl. Acad. Sci. USA 97: 10162 10167.
14. Breunis, W. B.,, M. H. Biezeveld,, J. Geissler,, I. M. Kuipers,, J. Lam,, J. Ottenkamp,, A. Hutchinson,, R. Welch,, S. J. Chanock,, and T. W. Kuijpers. 2007. Polymorphisms in chemokine receptor genes and susceptibility to Kawasaki disease. Clin. Exp. Immunol. 150: 83 90.
15. Brikos, C.,, and L. A. O’Neill. 2008. Signalling of toll-like receptors. Handb. Exp. Pharmacol. 2008( 183): 21 50.
16. Burns, K.,, S. Janssens,, B. Brissoni,, N. Olivos,, R. Beyaert, and J. Tschopp. 2003. Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J. Exp. Med. 197: 263 268.
17. Burns, K.,, F. Martinon,, C. Esslinger,, H. Pahl,, P. Schneider,, J. L. Bodmer,, F. DiMarco,, L. French,, and J. Tschopp. 1998. MyD88, an adapter protein involved in interleukin-1 signaling. J. Biol. Chem. 273: 12203 12209.
18. Calvano, J. E.,, D. J. Bowers,, S. M. Coyle,, M. Macor,, M. T. Reddell,, A. Kumar,, S. E. Calvano,, and S. F. Lowry. 2006. Response to systemic endotoxemia among humans bearing polymorphisms of the Toll-like receptor 4 (hTLR4). Clin. Immunol. 121: 186 190.
19. Cao, Z.,, J. Xiong,, M. Takeuchi,, T. Kurama,, and D. V. Goeddel. 1996. TRAF6 is a signal transducer for interleukin-1. Nature 383: 443 446.
20. Carty, M.,, R. Goodbody,, M. Schroder,, J. Stack,, P. N. Moynagh,, and A. G. Bowie. 2006. The human adaptor SARM negatively regulates adaptor protein TRIF-dependent Toll-like receptor signaling. Nat. Immunol. 7: 1074 1081.
21. Casanova, J. L.,, and L. Abel. 2007. Primary immunodeficiencies: a field in its infancy. Science 317: 617 619.
22. Cheong, J. Y.,, S. W. Cho,, J. Y. Choi,, J. A. Lee,, M. H. Kim,, J. E. Lee,, K. B. Hahm,, and J. H. Kim. 2007. RANTES, MCP-1, CCR2, CCR5, CXCR1 and CXCR4 gene polymorphisms are not associated with the outcome of hepatitis B virus infection: results from a large scale single ethnic population. J. Korean Med. Sci. 22: 529 535.
23. Chotivanich, K.,, R. Udomsangpetch,, K. Pattanapanyasat,, W. Chierakul,, J. Simpson,, S. Looareesuwan,, and N. White. 2002. Hemoglobin E: a balanced polymorphism protective against high parasitemias and thus severe P falciparum malaria. Blood 100: 1172 1176.
24. Chuntharapai, A.,, and K. J. Kim. 1995. Regulation of the expression of IL-8 receptor A/B by IL-8: possible functions of each receptor. J. Immunol. 155: 2587 2594.
25. Cirl, C.,, A. Wieser,, M. Yadav,, S. Duerr,, S. Schubert,, H. Fischer,, D. Stappert,, N., Wantia,, N. Rodriguez,, H. Wagner,, C. Svanborg,, and T. Miethke. 2008. Subversion of Toll-like receptor signaling by a unique family of bacterial Toll/interleukin-receptor domain-containing proteins. Nat. Med. 14: 399 406.
26. Copeman, J. B.,, F. Cucca,, C. M. Hearne,, R. J. Cornall,, P. W. Reed,, K. S. Ronningen,, D. E. Undlien,, L. Nistico,, R. Buzzetti,, R. Tosi, et al. 1995. Linkage disequilibrium mapping of a type 1 diabetes susceptibility gene (IDDM7) to chromosome 2q31-q33. Nat. Genet. 9: 80 85.
27. Cornelis, F.,, S. Faure,, M. Martinez,, J. F. Prud’homme,, P. Fritz,, C. Dib,, H. Alves,, P. Barrera,, N. de Vries,, A. Balsa,, D. Pascual-Salcedo,, K. Maenaut,, R. Westhovens,, P. Migliorini,, T. H. Tran,, A. Delaye,, N. Prince,, C. Lefevre,, G. Thomas,, M. Poirier,, S. Soubigou,, O. Alibert,, S. Lasbleiz,, S. Fouix,, C. Bouchier,, F. Liote,, M. N. Loste,, V. Lepage,, D. Charron,, G. Gyapay,, A. Lopes-Vaz,, D. Kuntz,, T. Bardin,, and J. Weissenbach. 1998. New susceptibility locus for rheumatoid arthritis suggested by a genome-wide linkage study. Proc. Natl. Acad. Sci. USA 95: 10746 10750.
28. Deng, L.,, C. Wang,, E. Spencer,, L. Yang,, A. Braun,, J. You,, C. Slaughter,, C. Pickart,, and Z. J. Chen. 2000. Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 103: 351 361.
29. Doffinger, R.,, A. Smahi,, C. Bessia,, F. Geissmann,, J. Feinberg,, A. Durandy,, C. Bodemer,, S. Kenwrick,, S. Dupuis-Girod,, S. Blanche,, P. Wood,, S. H. Rabia,, D. J. Headon,, P. A. Overbeek,, F. Le Deist,, S. M. Holland,, K. Belani,, D. S. Kumararatne,, A. Fischer,, R. Shapiro,, M. E. Conley,, E. Reimund,, H. Kalhoff,, M. Abinun,, A. Munnich,, A. Israel,, G. Courtois,, and J. L. Casanova. 2001. X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling. Nat. Genet. 27: 277 285.
30. Dunne, A.,, M. Ejdeback,, P. L. Ludidi,, L. A. O’Neill,, and N. J. Gay. 2003. Structural complementarity of Toll/interleukin-1 receptor domains in Toll-like receptors and the adaptors Mal and MyD88. J. Biol. Chem. 278: 41443 41451.
31. Edfeldt, K.,, A. M. Bennet,, P. Eriksson,, J. Frostegard,, B. Wiman,, A. Hamsten,, G. K. Hansson,, U. de Faire,, and Z. Q. Yan. 2004. Association of hypo-responsive toll-like receptor 4 variants with risk of myocardial infarction. Eur. Heart J. 25: 1447 1453.
32. Fearns, C.,, Q. Pan,, J. C. Mathison,, and T. H. Chuang. 2006. Triad3A regulates ubiquitination and proteasomal degradation of RIP1 following disruption of Hsp90 binding. J. Biol. Chem. 281: 34592 34600.
33. Ferwerda, B.,, M. B. McCall,, S. Alonso,, E. J. Giamarellos-Bourboulis,, M. Mouktaroudi,, N. Izagirre,, D. Syafruddin,, G. Kibiki,, T. Cristea,, A. Hijmans,, L. Hamann,, S. Israel,, G. ElGhazali,, M. Troye-Blomberg,, O. Kumpf,, B. Maiga,, A. Dolo,, O. Doumbo,, C. C. Hermsen,, A. F. Stalenhoef,, R. van Crevel,, H. G. Brunner,, D. Y. Oh,, R. R. Schumann,, C. de la Rua,, R. Sauerwein,, B. J. Kullberg,, A. J. van der Ven,, J. W. van der Meer,, and M. G. Netea. 2007. TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans. Proc. Natl. Acad. Sci. USA 104: 16645 16650.
34. Fijen, C. A.,, E. J. Kuijper,, A. J. Hannema,, A. G. Sjoholm,, and J. P. van Putten. 1989. Complement deficiencies in patients over ten years old with meningococcal disease due to uncommon serogroups. Lancet ii: 585 588.
35. Fischer, H.,, P. Ellstrom,, K. Ekstrom,, L. Gustafsson,, M. Gustafsson,, and C. Svanborg. 2007. Ceramide as a TLR4 agonist; a putative signalling intermediate between sphingolipid receptors for microbial ligands and TLR4. Cell. Microbiol. 9: 1239 1251.
36. Fitzgerald, K. A.,, E. M. Palsson-McDermott,, A. G. Bowie,, C. A. Jefferies,, A. S. Mansell,, G. Brady,, E. Brint,, A. Dunne,, P. Gray,, M. T. Harte,, D. McMurray,, D. E. Smith,, J. E. Sims,, T. A. Bird,, and L. A. O’Neill. 2001. Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature 413: 78 83.
37. Fitzgerald, K. A.,, D. C. Rowe,, B. J. Barnes,, D. R. Caffrey,, A. Visintin,, E. Latz,, B. Monks,, P. M. Pitha,, and D. T. Golenbock. 2003. LPS-TLR4 signaling to IRF-3/7 and NF-kappaB involves the toll adapters TRAM and TRIF. J. Exp. Med. 198: 1043 1055.
38. Frendeus, B.,, G. Godaly,, L. Hang,, D. Karpman,, A. C. Lundstedt,, and C. Svanborg. 2000. Interleukin 8 receptor deficiency confers susceptibility to acute experimental pyelonephritis and may have a human counterpart. J. Exp. Med. 192: 881 890.
39. Frendeus, B.,, G. Godaly,, L. Hang,, D. Karpman,, and C. Svanborg. 2001a. Interleukin-8 receptor deficiency confers susceptibility to acute pyelonephritis. J. Infect. Dis. 183( Suppl. 1): S56 S60.
40. Frendeus, B.,, C. Wachtler,, M. Hedlund,, H. Fischer,, P. Samuelsson,, M. Svensson,, and C. Svanborg. 2001b. Escherichia coli P fimbriae utilize the Toll-like receptor 4 pathway for cell activation. Mol. Microbiol. 40: 37 51.
41. Fu, W.,, Y. Zhang,, J. Zhang,, and W. F. Chen. 2005. Cloning and characterization of mouse homolog of the CXC chemokine receptor CXCR1. Cytokine 31: 9 17.
42. Gaffney, P. M.,, G. M. Kearns,, K. B. Shark,, W. A. Ortmann,, S. A. Selby,, M. L. Malmgren,, K. E. Rohlf,, T. C. Ockenden,, R. P. Messner,, R. A. King,, S. S. Rich,, and T. W. Behrens. 1998. A genome-wide search for susceptibility genes in human systemic lupus erythematosus sib-pair families. Proc. Natl. Acad. Sci. USA 95: 14875 14879.
43. Gay, N. J.,, and M. Gangloff. 2008. Structure of toll-like receptors. Handb. Exp. Pharmacol. 2008( 183): 181 200.
44. Godaly, G.,, G. Bergsten,, L. Hang,, H. Fischer,, B. Frendeus,, A. C. Lundstedt,, M. Samuelsson,, P. Samuelsson,, and C. Svanborg. 2001. Neutrophil recruitment, chemokine receptors, and resistance to mucosal infection. J. Leukoc. Biol. 69: 899 906.
45. Godaly, G.,, L. Hang,, B. Frendeus,, and C. Svanborg. 2000. Transepithelial neutrophil migration is CXCR1 dependent in vitro and is defective in IL-8 receptor knockout mice. J. Immunol. 165: 5287 5294.
46. Godaly, G.,, A. E. Proudfoot,, R. E. Offord,, C. Svanborg,, and W. W. Agace. 1997. Role of epithelial interleukin-8 (IL-8) and neutrophil IL-receptor A in Escherichia coli-induced transuroepithelial neutrophil migration. Infect. Immun. 65: 3451 3456.
47. Gray, P.,, A. Dunne,, C. Brikos,, C. A. Jefferies,, S. L. Doyle,, and L. A. O’Neill. 2006. MyD88 adapter-like (Mal) is phosphorylated by Bruton’s tyrosine kinase during TLR2 and TLR4 signal transduction. J. Biol. Chem. 281: 10489 10495.
48. Hacker, J.,, and J. B. Kaper. 2000. Pathogenicity islands and the evolution of microbes. Annu. Rev. Microbiol. 54: 641 679.
49. Hagberg, L.,, D. Briles,, and C. Svanborg-Edén. 1985. Evidence for separate genetic defects in C3H/HeJ and C3HeB/FeJ mice that affect the susceptibility to Gram-negative infections. J. Immunol. 134: 4118 4122.
50. Hang, L.,, B. Frendeus,, G. Godaly,, and C. Svanborg. 2000. Interleukin-8 receptor knockout mice have subepithelial neutrophil entrapment and renal scarring following acute pyelonephritis. J. Infect. Dis. 182: 1738 1748.
51. Hanson, L. A.,, S. Ahlstedt,, A. Fasth,, U. Jodal,, B. Kaijser,, P. Larsson,, U. Lindberg,, S. Olling,, A. Sohl-Akerlund,, and C. Svanborg-Eden. 1977. Antigens of Escherichia coli, human immune response, and the pathogenesis of urinary tract infections. J. Infect. Dis. 136( Suppl.): S144 S149.
52. Haraoka, M.,, L. Hang,, B. Frendeus,, G. Godaly,, M. Burdick,, R. Strieter,, and C. Svanborg. 1999. Neutrophil recruitment and resistance to urinary tract infection. J. Infect. Dis. 180: 1220 1229.
53. Hawn, T. R.,, D. Scholes,, S. S. Li,, H. Wang,, Y. Yang,, P. L. Roberts,, A. E. Stapleton,, M. Janer,, A. Aderem,, W. E. Stamm,, L. P. Zhao,, and T. M. Hooton. 2009a. Toll-like receptor polymorphisms and susceptibility to urinary tract infections in adult women. PLoS One 4: e5990.
54. Hawn, T. R.,, D. Scholes,, H. Wang,, S. S. Li,, A. E. Stapleton,, M. Janer,, A. Aderem,, W. E. Stamm,, L. P. Zhao,, and T. M. Hooton. 2009b. Genetic variation of the human urinary tract innate immune response and asymptomatic bacteriuria in women. PLoS One 4: e8300.
55. Hawn, T. R.,, A. Verbon,, K. D. Lettinga,, L. P. Zhao,, S. S. Li,, R. J. Laws,, S. J. Skerrett,, B. Beutler,, L. Schroeder,, A. Nachman,, A. Ozinsky,, K. D. Smith,, and A. Aderem. 2003. A common dominant TLR5 stop codon polymorphism abolishes flagellin signaling and is associated with susceptibility to legionnaires’ disease. J. Exp. Med. 198: 1563 1572.
56. Hedlund, M.,, B. Frendeus,, C. Wachtler,, L. Hang,, H. Fischer,, and C. Svanborg. 2001. Type 1 fimbriae deliver an LPS-and TLR4-dependent activation signal to CD14-negative cells. Mol. Microbiol. 39: 542 552.
57. Hedlund, M.,, Å. Nilsson,, R. D. Duan,, and C. Svanborg. 1998. Sphingomyelin, glycosphingolipids and ceramide signalling in cells exposed to P fimbriated Escherichia coli. Mol. Microbiol. 29: 1297 1306.
58. Hedlund, M.,, M. Svensson,, A. Nilsson,, R. D. Duan,, and C. Svanborg. 1996. Role of the ceramide-signaling pathway in cytokine responses to P-fimbriated Escherichia coli. J. Exp. Med. 183: 1037 1044.
59. Hedlund, M.,, C. Wachtler,, E. Johansson,, L. Hang,, J. E. Somerville,, R. P. Darveau,, and C. Svanborg. 1999. P fimbriae-dependent, lipopolysaccharide-independent activation of epithelial cytokine responses. Mol. Microbiol. 33: 693 703.
60. Hoebe, K.,, X. Du,, P. Georgel,, E. Janssen,, K. Tabeta,, S. O. Kim,, J. Goode,, P. Lin,, N. Mann,, S. Mudd,, K. Crozat,, S. Sovath,, J. Han,, and B. Beutler. 2003. Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature 424: 743 748.
61. Holmes, W. E.,, J. Lee,, W. J. Kuang,, G. C. Rice,, and W. I. Wood. 1991. Structure and functional expression of a human interleukin-receptor. Science 253: 1278 1280.
62. Hopkins, W. J.,, J. Elkahwaji,, L. M. Beierle,, G. E. Leverson,, and D. T. Uehling. 2007. Vaginal mucosal vaccine for recurrent urinary tract infections in women: results of a phase 2 clinical trial. J. Urol. 177: 1349 1353; quiz 1591.
63. Hopkins, W. J.,, A. Gendron-Fitzpatrick,, E. Balish,, and D. T. Uehling. 1998. Time course and host responses to Escherichia coli urinary tract infection in genetically distinct mouse strains. Infect. Immun. 66: 2798 2802.
64. Hopkins, W. J.,, D. T. Uehling,, and D. S. Wargowski. 1999. Evaluation of a familial predisposition to recurrent urinary tract infections in women. Am. J. Med. Genet. 83: 422 424.
65. Horng, T.,, G. M. Barton,, and R. Medzhitov. 2001. TIRAP: an adapter molecule in the Toll signaling pathway. Nat. Immunol. 2: 835 841.
66. Janssens, S.,, K. Burns,, E. Vercammen,, J. Tschopp,, and R. Beyaert. 2003. MyD88S, a splice variant of MyD88, differentially modulates NF-κB-and AP-1-dependent gene expression. FEBS Lett. 548: 103 107.
67. Kagan, J. C.,, and R. Medzhitov. 2006. Phosphoinositide-mediated adaptor recruitment controls Toll-like receptor signaling. Cell 125: 943 955.
68. Kaijser, B.,, S. Ahlstedt,, U. Jodal,, and S. Mårild. 1978. Possible clinical significance of O and K antibodies against infecting Escherichia coli in antimicrobial treatment of acute childhood pyelonephritis. Infection 6: S125 S128.
69. Kaijser, B.,, L. A. Hanson,, U. Jodal,, G. Lidin-Janson,, and J. B. Robbins. 1977. Frequency of E. coli K antigens in urinary-tract infections in children. Lancet i: 663 666.
70. Kaijser, B.,, P. Larsson,, S. Olling,, and R. Schneerson. 1983. Protection against acute, ascending pyelonephritis caused by Escherichia coli in rats, using isolated capsular antigen conjugated to bovine serum albumin. Infect. Immun. 39: 142 146.
71. Kalis, C.,, B. Kanzler,, A. Lembo,, A. Poltorak,, C. Galanos,, and M. A. Freudenberg. 2003. Toll-like receptor 4 expression levels determine the degree of LPS-susceptibility in mice. Eur. J. Immunol. 33: 798 805.
72. Karin, M.,, and Y. Ben-Neriah. 2000. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu. Rev. Immunol. 18: 621 663.
73. Karoly, E.,, A. Fekete,, N. F. Banki,, B. Szebeni,, A. Vannay,, A. J. Szabo,, T. Tulassay,, and G. S. Reusz. 2007. Heat shock protein 72 (HSPA1B) gene polymorphism and Toll-like receptor (TLR) 4 mutation are associated with increased risk of urinary tract infection in children. Pediatr. Res. 61: 371 374.
74. Kato, H.,, N. Tsuchiya,, and K. Tokunaga. 2000. Single nucleotide polymorphisms in the coding regions of human CXC-chemokine receptors CXCR1, CXCR2 and CXCR3. Genes Immun. 1: 330 337.
75. Kawai, T.,, O. Adachi,, T. Ogawa,, K. Takeda,, and S. Akira. 1999. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 11: 115 122.
76. Kawai, T.,, and S. Akira. 2009. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int. Immunol. 21: 317 337.
77. Kawai, T.,, S. Sato,, K. J. Ishii,, C. Coban,, H. Hemmi,, M. Yamamoto,, K. Terai,, M. Matsuda,, J. Inoue,, S. Uematsu,, O. Takeuchi,, and S. Akira. 2004. Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat. Immunol. 5: 1061 1068.
78. Kim, H. M.,, B. S. Park,, J. I. Kim,, S. E. Kim,, J. Lee,, S. C. Oh,, P. Enkhbayar,, N. Matsushima,, H. Lee,, O. J. Yoo,, and J. O. Lee. 2007. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell 130: 906 917.
79. Ko, Y. C.,, N. Mukaida,, S. Ishiyama,, A. Tokue,, T. Kawai,, K. Matsushima,, and T. Kasahara. 1993. Elevated interleukin-8 levels in the urine of patients with urinary tract infections. Infect. Immun. 61: 1307 1314.
80. Kobayashi, K.,, L. D. Hernandez,, J. E. Galan,, C. A. Janeway, Jr.,, R. Medzhitov,, and R. A. Flavell. 2002. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 110: 191 202.
81. Langermann, S.,, R. Mollby,, J. E. Burlein,, S. R. Palaszynski,, C. G. Auguste,, A. DeFusco,, R. Strouse,, M. A. Schenerman,, S. J. Hultgren,, J. S. Pinkner,, J. Winberg,, L. Guldevall,, M. Soderhall,, K. Ishikawa,, S. Normark,, and S. Koenig. 2000. Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli. J. Infect. Dis. 181: 774 778.
82. Langermann, S.,, S. Palaszynski,, M. Barnhart,, G. Auguste,, J. S. Pinkner,, J. Burlein,, P. Barren,, S. Koenig,, S. Leath,, C. H. Jones,, and S. J. Hultgren. 1997. Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination. Science 276: 607 611.
83. Lichtinger, M.,, R. Ingram,, M. Hornef,, C. Bonifer,, and M. Rehli. 2007. Transcription factor PU.1 controls transcription start site positioning and alternative TLR4 promoter usage. J. Biol. Chem. 282: 26874 26883.
84. Lien, E.,, T. J. Sellati,, A. Yoshimura,, T. H. Flo,, G. Rawadi,, R. W. Finberg,, J. D. Carroll,, T. Espevik,, R. R. Ingalls,, J. D. Radolf,, and D. T. Golenbock. 1999. Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products. J. Biol. Chem. 274: 33419 33425.
85. Lomberg, H.,, L. A. Hanson,, B. Jacobsson,, U. Jodal,, H. Leffler,, and C. S. Eden. 1983. Correlation of P blood group, vesicoureteral reflux, and bacterial attachment in patients with recurrent pyelonephritis. N. Engl. J. Med. 308: 1189 1192.
86. Lomberg, H.,, U. Jodal,, C. Svanborg-Edén,, H. Leffler,, and B. Samuelsson. 1981. P1 blood group and urinary tract infection. Lancet i: 551 552.
87. Lundstedt, A. C.,, I. Leijonhufvud,, B. Ragnarsdottir,, D. Karpman,, B. Andersson,, and C. Svanborg. 2007a. Inherited susceptibility to acute pyelonephritis: a family study of urinary tract infection. J. Infect. Dis. 195: 1227 1234.
88. Lundstedt, A. C.,, S. McCarthy,, M. C. Gustafsson,, G. Godaly,, U. Jodal,, D. Karpman,, I. Leijonhufvud,, C. Linden,, J. Martinell,, B. Ragnarsdottir,, M. Samuelsson,, L. Truedsson,, B. Andersson,, and C. Svanborg. 2007b. A genetic basis of susceptibility to acute pyelonephritis. PLoS One 2: e825.
89. Marsik, C.,, B. Jilma,, C. Joukhadar,, C. Mannhalter,, O. Wagner,, and G. Endler. 2005. The Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms influence the late inflammatory response in human endotoxemia. Clin. Chem. 51: 2178 2180.
90. Matsushima, N.,, T. Tanaka,, P. Enkhbayar,, T. Mikami,, M. Taga,, K. Yamada,, and Y. Kuroki. 2007. Comparative sequence analysis of leucine-rich repeats (LRRs) within vertebrate toll-like receptors. BMC Genomics 8: 124.
91. McGettrick, A. F.,, E. K. Brint,, E. M. Palsson-McDermott,, D. C. Rowe,, D. T. Golenbock,, N. J. Gay,, K. A. Fitzgerald,, and L. A. O’Neill. 2006. Trif-related adapter molecule is phosphorylated by PKCε during Toll-like receptor 4 signaling. Proc. Natl. Acad. Sci. USA 103: 9196 9201.
92. Mockenhaupt, F. P.,, J. P. Cramer,, L. Hamann,, M. S. Stegemann,, J. Eckert,, N. R. Oh,, R. N. Otchwemah,, E. Dietz,, S. Ehrhardt,, N. W. Schroder,, U. Bienzle,, and R. R. Schumann. 2006. Toll-like receptor (TLR) polymorphisms in African children: common TLR-4 variants predispose to severe malaria. Proc. Natl. Acad. Sci. USA 103: 177 182.
93. Moepps, B.,, E. Nuesseler,, M. Braun,, and P. Gierschik. 2006. A homolog of the human chemokine receptor CXCR1 is expressed in the mouse. Mol. Immunol. 43: 897 914.
94. Mogensen, T. H. 2009. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin. Microbiol. Rev. 22: 240 273.
95. Morgan, B. P.,, and A. Orren. 1998. Vaccination against meningococcus in complement-deficient individuals. Clin. Exp. Immunol. 114: 327 329.
96. Murphy, P. M.,, and H. L. Tiffany. 1991. Cloning of complementary DNA encoding a functional human interleukin-8 receptor. Science 253: 1280 1283.
97. Oganesyan, G.,, S. K. Saha,, B. Guo,, J. Q. He,, A. Shahangian,, B. Zarnegar,, A. Perry,, and G. Cheng. 2006. Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral response. Nature 439: 208 211.
98. Olson, T. S.,, and K. Ley. 2002. Chemokines and chemokine receptors in leukocyte trafficking. Am. J. Physiol. Regul. Integr. Comp. Physiol. 283: R7 R28.
99. Ozinsky, A.,, K. D. Smith,, D. Hume,, and D. M. Underhill. 2000. Co-operative induction of pro-inflammatory signaling by Toll-like receptors. J. Endotoxin Res. 6: 393 396.
100. Palsson-McDermott, E. M.,, S. L. Doyle,, A. F. McGettrick,, M. Hardy,, H. Husebye,, K. Banahan,, M. Gong,, D. Golenbock,, T. Espevik,, and L. A. O’Neill. 2009. TAG, a splice variant of the adaptor TRAM, negatively regulates the adaptor MyD88-independent TLR4 pathway. Nat. Immunol. 10: 579 586.
101. Pecha, B.,, D. Low,, and P. O’Hanley. 1989. Gal-Gal pili vaccines prevent pyelonephritis by piliated Escherichia coli in a murine model. Single-component Gal-Gal pili vaccines prevent pyelonephritis by homologous and heterologous piliated E. coli strains. J. Clin. Investig. 83: 2102 2108.
102. Picard, C.,, A. Puel,, M. Bonnet,, C. L. Ku,, J. Bustamante,, K. Yang,, C. Soudais,, S. Dupuis,, J. Feinberg,, C. Fieschi,, C. Elbim,, R. Hitchcock,, D. Lammas,, G. Davies,, A. Al-Ghonaium,, H. Al-Rayes,, S. Al-Jumaah,, S. Al-Hajjar,, I. Z. Al-Mohsen,, H. H. Frayha,, R. Rucker,, T. R. Hawn,, A. Aderem,, H. Tufenkeji,, S. Haraguchi,, N. K. Day,, R. A. Good,, M. A. Gougerot-Pocidalo,, A. Ozinsky,, and J. L. Casanova. 2003. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 299: 2076 2079.
103. Poltorak, A.,, X. He,, I. Smirnova,, M. Y. Liu,, C. Van Huffel,, X. Du,, D. Birdwell,, E. Alejos,, M. Silva,, C. Galanos,, M. Freudenberg,, P. Ricciardi-Castagnoli,, B. Layton,, and B. Beutler. 1998. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282: 2085 2088.
104. Pugin, J.,, M. Schürer,, D. Leturcq,, A. Moriarty,, R. J. Ulevitch,, and P. S. Tobias. 1993. Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14. Proc. Natl. Acad. Sci. USA 90: 2744 2748.
105. Ragnarsdottir, B.,, M. Samuelsson,, M. C. Gustafsson,, I. Leijonhufvud,, D. Karpman,, and C. Svanborg. 2007. Reduced toll-like receptor 4 expression in children with asymptomatic bacteriuria. J. Infect. Dis. 196: 475 484.
106. Rallabhandi, P.,, J. Bell,, M. S. Boukhvalova,, A. Medvedev,, E. Lorenz,, M. Arditi,, V. G. Hemming,, J. C. Blanco,, D. M. Segal,, and S. N. Vogel. 2006. Analysis of TLR4 polymorphic variants: new insights into TLR4/MD-2/CD14 stoichiometry, structure, and signaling. J. Immunol. 177: 322 332.
107. Read, R. C.,, J. Pullin,, S. Gregory,, R. Borrow,, E. B. Kaczmarski,, F. S. di Giovine,, S. K. Dower,, C. Cannings,, and A. G. Wilson. 2001. A functional polymorphism of toll-like receptor 4 is not associated with likelihood or severity of meningococcal disease. J. Infect. Dis. 184: 640 642.
108. Rehli, M.,, A. Poltorak,, L. Schwarzfischer,, S. W. Krause,, R. Andreesen,, and B. Beutler. 2000. PU.1 and interferon consensus sequence-binding protein regulate the myeloid expression of the human Toll-like receptor 4 gene. J. Biol. Chem. 275: 9773 9781.
109. Roger, T.,, J. David,, M. P. Glauser,, and T. Calandra. 2001. MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature 414: 920 924.
110. Roger, T.,, I. Miconnet,, A. L. Schiesser,, H. Kai,, K. Miyake,, and T. Calandra. 2005. Critical role for Ets, AP-1 and GATA-like transcription factors in regulating mouse Toll-like receptor 4 (Tlr4) gene expression. Biochem. J. 387: 355 365.
111. Rowe, D. C.,, A. F. McGettrick,, E. Latz,, B. G. Monks,, N. J. Gay,, M. Yamamoto,, S. Akira,, L. A. O’Neill,, K. A. Fitzgerald,, and D. T. Golenbock. 2006. The myristoylation of TRIF-related adaptor molecule is essential for Toll-like receptor 4 signal transduction. Proc. Natl. Acad. Sci. USA 103: 6299 6304.
112. Rowe, J. A.,, D. H. Opi,, and T. N. Williams. 2009. Blood groups and malaria: fresh insights into pathogenesis and identification of targets for intervention. Curr. Opin. Hematol. 16: 480 487.
113. Roy, M. F.,, L. Lariviere,, R. Wilkinson,, M. Tam,, M. M. Stevenson,, and D. Malo. 2006. Incremental expression of Tlr4 correlates with mouse resistance to Salmonella infection and fine regulation of relevant immune genes. Genes Immun. 7: 372 383.
114. Samuelsson, P.,, L. Hang,, B. Wullt,, H. Irjala,, and C. Svanborg. 2004. Toll-like receptor 4 expression and cytokine responses in the human urinary tract mucosa. Infect. Immun. 72: 3179 3186.
115. Sato, S.,, M. Sugiyama,, M. Yamamoto,, Y. Watanabe,, T. Kawai,, K. Takeda,, and S. Akira. 2003. Toll/IL-1 receptor domain-containing adaptor inducing IFN-beta (TRIF) associates with TNF receptor-associated factor 6 and TANK-binding kinase 1, and activates two distinct transcription factors, NF-kappa B and IFN-regulatory factor-3, in the Toll-like receptor signaling. J. Immunol. 171: 4304 4310.
116. Schenck, M.,, A. Carpinteiro,, H. Grassme,, F. Lang,, and E. Gulbins. 2007. Ceramide: physiological and pathophysiological aspects. Arch. Biochem. Biophys. 462: 171 175.
117. Schilling, J. D.,, S. M. Martin,, C. S. Hung,, R. G. Lorenz,, and S. J. Hultgren. 2003. Toll-like receptor 4 on stromal and hematopoietic cells mediates innate resistance to uropathogenic Escherichia coli. Proc. Natl. Acad. Sci. USA 100: 4203 4208.
118. Shahin, R.,, I. Engberg,, L. Hagberg,, and C. Svanborg-Edén. 1987. Neutrophil recruitment and bacterial clearance correlated with LPS responsiveness in local gram-negative infection. J. Immunol. 10: 3475 3480.
119. Sheedy, F. J.,, and L. A. O’Neill. 2007. The Troll in Toll: Mal and Tram as bridges for TLR2 and TLR4 signaling. J. Leukoc. Biol. 82: 196 203.
120. Shimazu, R.,, S. Akashi,, H. Ogata,, Y. Nagai,, K. Fukudome,, K. Miyake,, and M. Kimoto. 1999. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J. Exp. Med. 189: 1777 1782.
121. Silverblatt, F.,, and L. Cohen. 1979. Anti pili antibody affords protection against experimental ascending pyelonephritis. J. Clin. Investig. 64: 333 336.
122. Sjoholm, A. G.,, G. Jonsson,, J. H. Braconier,, G. Sturfelt,, and L. Truedsson. 2006. Complement deficiency and disease: an update. Mol. Immunol. 43: 78 85.
123. Smith, R. J.,, L. M. Sam,, K. L. Leach,, and J. M. Justen. 1992. Postreceptor events associated with human neutrophil activation by interleukin-8. J. Leukoc. Biol. 52: 17 26.
124. Smithson, A.,, M. R. Sarrias,, J. Barcelo,, B. Suarez,, J. P. Horcajada,, S. M. Soto,, A. Soriano,, J. Vila,, J. A. Martinez,, J. Vives,, J. Mensa,, and F. Lozano. 2005. Expression of interleukin-8 receptors (CXCR1 and CXCR2) in premenopausal women with recurrent urinary tract infections. Clin. Diagn. Lab. Immunol. 12: 1358 1363.
125. Sprenger, H.,, A. R. Lloyd,, R. G. Meyer,, J. A. Johnston,, and D. J. Kelvin. 1994. Genomic structure, characterization, and identification of the promoter of the human IL-8 receptor A gene. J. Immunol. 153: 2524 2532.
126. Stapleton, A.,, E. Nudelman,, H. Clausen,, S. Hakomori,, and W. E. Stamm. 1992. Binding of uropathogenic Escherichia coli R45 to glycolipids extracted from vaginal epithelial cells is dependent on histo-blood group secretor status. J. Clin. Investig. 90: 965 972.
127. Svanborg, C.,, G. Bergsten,, H. Fischer,, G. Godaly,, M. Gustafsson,, D. Karpman,, A. C. Lundstedt,, B. Ragnarsdottir,, M. Svensson,, and B. Wullt. 2006. Uropathogenic Escherichia coli as a model of host-parasite interaction. Curr. Opin. Microbiol. 9: 33 39.
128. Svanborg Eden, C.,, D. Briles,, L. Hagberg,, J. McGhee,, and S. Michalec. 1985. Genetic factors in host resistance to urinary tract infection. Infection 13( Suppl. 2): S171 S176.
129. Svensson, M.,, H. Irjala,, P. Alm,, B. Holmqvist,, A.-C. Lundstedt,, and C. Svanborg. 2005. Natural history of renal scarring in susceptible mIL-8Rh−/− mice. Kidney Int. 67: 103 110.
130. Tal, G.,, A. Mandelberg,, I. Dalal,, K. Cesar,, E. Somekh,, A. Tal,, A. Oron,, S. Itskovich,, A. Ballin,, S. Houri,, A. Beigelman,, O. Lider,, G. Rechavi,, and N. Amariglio. 2004. Association between common Toll-like receptor 4 mutations and severe respiratory syncytial virus disease. J. Infect. Dis. 189: 2057 2063.
131. Thomassen, E.,, B. R. Renshaw,, and J. E. Sims. 1999. Identification and characterization of SIGIRR, a molecule representing a novel subtype of the IL-1R superfamily. Cytokine 11: 389 399.
132. Thumbikat, P.,, C. Waltenbaugh,, A. J. Schaeffer,, and D. J. Klumpp. 2006. Antigen-specific responses accelerate bacterial clearance in the bladder. J. Immunol. 176: 3080 3086.
133. Uehling, D. T.,, W. J. Hopkins,, E. Balish,, Y. Xing,, and D. M. Heisey. 1997. Vaginal mucosal immunization for recurrent urinary tract infection: phase II clinical trial. J. Urol. 157: 2049 2052.
134. Uehling, D. T.,, W. J. Hopkins,, L. M. Beierle,, J. V. Kryger,, and D. M. Heisey. 2001. Vaginal mucosal immunization for recurrent urinary tract infection: extended phase II clinical trial. J. Infect. Dis. 183( Suppl. 1): S81 S83.
135. Uehling, D. T.,, W. J. Hopkins,, L. A. Dahmer,, and E. Balish. 1994. Phase I clinical trial of vaginal mucosal immunization for recurrent urinary tract infection. J. Urol. 152: 2308 2311.
136. Uehling, D. T.,, W. J. Hopkins,, J. E. Elkahwaji,, D. M. Schmidt,, and G. E. Leverson. 2003. Phase 2 clinical trial of a vaginal mucosal vaccine for urinary tract infections. J. Urol. 170: 867 869.
137. Underhill, D. M.,, A. Ozinsky,, A. M. Hajjar,, A. Stevens,, C. B. Wilson,, M. Bassetti,, and A. Aderem. 1999. The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature 401: 811 815.
138. Vasilescu, A.,, Y. Terashima,, M. Enomoto,, S. Heath,, V. Poonpiriya,, H. Gatanaga,, H. Do,, G. Diop,, T. Hirtzig,, P. Auewarakul,, D. Lauhakirti,, T. Sura,, P. Charneau,, S. Marullo,, A. Therwath,, S. Oka,, S. Kanegasaki,, M. Lathrop,, K. Matsushima,, J. F. Zagury,, and F. Matsuda. 2007. A haplotype of the human CXCR1 gene protective against rapid disease progression in HIV-1 patients. Proc. Natl. Acad. Sci. USA 104: 3354 3359.
139. von Bernuth, H.,, C. Picard,, Z. Jin,, R. Pankla,, H. Xiao,, C. L. Ku,, M. Chrabieh,, I. B. Mustapha,, P. Ghandil,, Y. Camcioglu,, J. Vasconcelos,, N. Sirvent,, M. Guedes,, A. B. Vitor,, M. J. Herrero-Mata,, J. I. Arostegui,, C. Rodrigo,, L. Alsina,, E. Ruiz-Ortiz,, M. Juan,, C. Fortuny,, J. Yague,, J. Anton,, M. Pascal,, H. H. Chang,, L. Janniere,, Y. Rose,, B. Z. Garty,, H. Chapel,, A. Issekutz,, L. Marodi,, C. Rodriguez-Gallego,, J. Banchereau,, L. Abel,, X. Li,, D. Chaussabel,, A. Puel,, and J. L. Casanova. 2008. Pyogenic bacterial infections in humans with MyD88 deficiency. Science 321: 691 696.
140. Wald, D.,, J. Qin,, Z. Zhao,, Y. Qian,, M. Naramura,, L. Tian,, J. Towne,, J. E. Sims,, G. R. Stark,, and X. Li. 2003. SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling. Nat. Immunol. 4: 920 927.
141. Wang, C.,, L. Deng,, M. Hong,, G. R. Akkaraju,, J. Inoue,, and Z. J. Chen. 2001. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 412: 346 351.
142. Wiles, T. J.,, R. R. Kulesus,, and M. A. Mulvey. 2008. Origins and virulence mechanisms of uropathogenic Escherichia coli. Exp. Mol. Pathol. 85: 11 19.
143. Wilkinson, N. C.,, and J. Navarro. 1999. PU.1 regulates the CXCR1 promoter. J. Biol. Chem. 274: 438 443.
144. Yadav, M.,, J. Zhang,, H. Fischer,, W. Huang,, N. Lutay,, C. Cirl,, J. Lum,, T. Miethke,, and C. Svanborg. 2010. Inhibition of TIR domain signaling by TcpC: MyD88-dependent and independent effects on Escherichia coli virulence. PLoS Pathog. 6: e1001120.
145. Yamamoto, M.,, S. Sato,, H. Hemmi,, K. Hoshino,, T. Kaisho,, H. Sanjo,, O. Takeuchi,, M. Sugiyama,, M. Okabe,, K. Takeda,, and S. Akira. 2003. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 301: 640 643.
146. Yamamoto, M.,, S. Sato,, H. Hemmi,, S. Uematsu,, K. Hoshino,, T. Kaisho,, O. Takeuchi,, K. Takeda,, and S. Akira. 2003. TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway. Nat. Immunol. 4: 1144 1150.
147. Yamamoto, M.,, S. Sato,, K. Mori,, K. Hoshino,, O. Takeuchi,, K. Takeda,, and S. Akira. 2002. Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J. Immunol. 169: 6668 6672.
148. Zhang, D.,, G. Zhang,, M. S. Hayden,, M. B. Greenblatt,, C. Bussey,, R. A. Flavell,, and S. Ghosh. 2004. A toll-like receptor that prevents infection by uropathogenic bacteria. Science 303: 1522 1526.


Generic image for table

Some of the known TLR ligands (PAMPs)

Citation: Ragnarsdóttir B, Svanborg C. 2012. Host Genetic Variation, Innate Immunity, and Susceptibility to Urinary Tract Infection, p 358-378. In Hacker J, Dobrindt U, Kurth R (ed), Genome Plasticity and Infectious Diseases. ASM Press, Washington, DC. doi: 10.1128/9781555817213.ch21

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error